<DOC>
	<DOCNO>NCT00005824</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness chemotherapy follow peripheral stem cell transplantation treat patient recurrent refractory AIDS-related lymphoma .</brief_summary>
	<brief_title>Chemotherapy Followed By Peripheral Stem Cell Transplantation Treating Patients With Recurrent Refractory AIDS-Related Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability intensive chemotherapy autologous peripheral blood stem cell transplantation patient recurrent refractory AIDS-related lymphoma . - Determine response response duration patient treat regimen . - Determine effect treatment regimen HIV RNA CD4 cell patient . OUTLINE : Patients receive mobilization chemotherapy consist cyclophosphamide IV 2 hour follow 2 day later daily filgrastim ( G-CSF ) subcutaneously ( SC ) blood count recover . Patients undergo leukopheresis collect CD34+ cell . Patients receive condition chemotherapy consist oral busulfan every 6 hour day -7 , -6 , -5 , -4 total 14 dos cyclophosphamide IV 1 hour day -3 -2 . Patients undergo autologous stem cell infusion day 0 . G-CSF administer IV SC daily begin day 1 continue blood count recover . Patients follow monthly 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 5-25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , AIDS-Related</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Intermediate highgrade nonHodgkin 's lymphoma Hodgkin 's disease Failed achieve complete remission initial therapy OR Relapsed initial therapy May complete remission salvage therapy Sensitive recent chemotherapy Improvement least 25 % bidimensional tumor measurement OR Improvement evaluable disease sustain 4 week Measurable evaluable disease HIV1 positive CD4 great 50 cells/mm^3 ( unless receive optimal antiretroviral therapy ) HIV RNA le 110,000 copies/mL ( unless receive optimal antiretroviral therapy ) No active leptomeningeal parenchymal CNS involvement NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Physiologic 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Hepatic : AST great 3 time upper limit normal Bilirubin great 2.0 mg/dL ( unless receive indinavir ) Renal : Creatinine great 2.0 mg/dL Cardiovascular : No history cardiac disease LVEF least 45 % Pulmonary : No history symptomatic pulmonary disease DLCO least 60 % Other : No active opportunistic infection No cytomegalovirus retinitis pneumonitis require maintenance therapy No sensitivity E. coliderived product Not pregnant Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 1 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Chronic suppressive therapy infection allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>HIV-associated Hodgkin lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
</DOC>